|Generic name||Denileukin diftitox|
|Brand name(s), other common name(s)||Ontak®|
|Drug type||DNA-damaging agent|
|How the drug is given||Intravenously (IV)|
Denileukin diftitox is FDA approved to treat people who have persistent or recurrent cutaneous T-cell lymphoma whose malignant cells express the CD25 component of the IL-2 receptor.
Side effects needing medical attention:Back pain or lower back pain or side pain accompanied by fever or chills; chest pain; dizziness or faintness; difficulty swallowing; fast or irregular heartbeat; fever or chills; infection; rash; shortness of breath; swelling of face, feet or lower legs; warmth and flushing of skin; severe abdominal pain; black, tarry stools; cloudy urine; blood in urine or stool; cough or hoarseness accompanied by fever or chills; severe headache; loss of coordination; painful or difficult urination accompanied by fever or chills; pain in groin or leg; pinhead-sized red spots on skin; slurring of speech; sudden vision changes; swelling or pain at injection site; unusual bleeding or bruising; weakness of arms or legs; difficulty swallowing; loss of strength or energy; nausea; pain in joints and muscles; unusual tiredness or weakness; vomiting; cough; diarrhea; sore throat; trouble sleeping.